D-Street Newsmakers: Tech Mahindra, PNB and Bajaj Auto among 10 stocks that hogged the limelight today

Share market today: Indian equities, taking cues from the global markets, ended in the red on the last trading session of the week. Nifty gave up 101.35 points, or 0.47 per cent during the session and settled at 21,352.6, while Sensex lost 359.64 points, or 0.51 per cent to close at 70,700.67.

Here are the 10 stocks that buzzed the most today.

Grindwell Norton: Shares of the company ended 3 per cent higher at Rs 2,368.1 apiece amid a spike in volume.

Aarti Drugs: Shares of the pharma company ended with a cut of 6 per cent at Rs 504 even as the company’s Q3 consolidated net profit rose to Rs 36.71 crore.

ACC: Shares of the cement maker were locked in the 10 per cent upper circuit at the fresh 52-week high price of Rs 2,459.75. The company reported good Q3 numbers, with PAT climbing over 4-fold to Rs 537.67 crore.

Tech Mahindra: Shares of the large-cap IT player ended over 6 per cent lower at Rs 1,323 after the company posted a weak set of Q3 earnings.

Bajaj Auto: Shares of the 2 and 3-wheeler company ended with around 5 per cent gains at Rs 7,568 as Jefferies gave a ‘buy’ call on the counter with a raised target of Rs 9,000.

DLF: Shares of the realty player settled over 1 per cent higher at Rs 755.15 after the company posted healthy Q3 earnings.

HPCL: Shares of the oil marketing company (OMC) ended around 5 per cent lower at Rs 430.25 even as the company’s standalone net profit in the quarter ended December scaled substantially YoY to Rs 529 crore.

Balkrishna Industries: Shares of the tyre company ended over 6.5 per cent lower at Rs 2,535 as the company’s Q3 PAT slipped 8 per cent sequentially to Rs 309.09 crore.

PNB: Shares of the state-run lender settled over 2 per cent higher at Rs 104.61 after the bank’s standalone net profit for the December quarter jumped 253 per cent year-on-year (YoY).

Zydus Lifesciences: Shares of the pharma company fell 2 per cent to close at Rs 736.3, even as the company received final approval from the USFDA to manufacture and market Gabapentin tablets, 300 mg and 600 mg.